Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up

Urology

Volumn 56, Issue 2, 2000, Pages 289-294

  Gleave, Martin E ^b   La Bianca, Shane E ^a   Goldenberg, S Larry ^a   Jones, Edward C ^a   Bruchovsky, Nicholas ^a   Sullivan, Lorne D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTACT EXAMINATION; CONTROLLED CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DRUG THERAPY, COMBINATION; FLUTAMIDE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 0033914728     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00627-0     Document Type: Article

References (30)

1. Macfarlane M.T., Abi-aad A., Stein A., et al. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol. 150:1993;132-134.
2. Oesterling J.E., Andrews P.E., Suman V.J., et al. Preoperative androgen deprivation therapy artificial lowering of serum prostate specific antigen without downstaging the tumor . J Urol. 149:1992;779-782.
3. Fair W.R., Aprikian A., Sogani P., et al. The role of neoadjuvant hormonal manipulation in localized prostate cancer. Cancer. 71:1993;1031-1035.
4. Labrie F., Cusan L., Gomez J.L., et al. Down-staging of early stage prostate cancer the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist . Clin Invest Med. 16:1993;499-509.
5. Soloway M.S., Sharifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 154:1995;424-428.
6. Goldenberg S.L., Klotz L.H., Jewitt M.A.S. Randomized controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer. J Urol. 156:1996;873-877.
7. Soloway M.S., Sharifie R., Wajsman Z., et al. Randomized prospective study radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer . J Urol. 157:1997;619A.
8. Goldenberg S.L., Klotz L., Bullock M.J., et al. Neoadjuvant cyproterone acetate therapy prior to radical prostatectomy reduces tumour burden and margin positivity without altering 6 and 12 month post-treatment PSA results of a randomized trial . J Urol. 155:1997;399A.
9. Klotz L.H., Goldenberg S.L., Jewett M., et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy 36 month post treatment PSA results . Urology. 53:1999;757-763.
10. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathological effects of eight months of androgen withdrawal therapy prior to radical prostatectomy in clinically confined prostate cancer. J Urol. 155:1996;213-219.
11. Gleave M.E., Hsieh J.T., Wu H.C., et al. Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 52:1992;1598-1605.
12. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Long term neoadjuvant hormone therapy prior to radical prostatectomy analysis of outcome by preoperative risk factors . Molec Urol. 2:1998;171-179.
13. Jones E.C. Resection margin status in radical prostatectomy specimens relationship to type of operation, tumor size, tumor grade and local tumor extension . J Urol. 144:1990;89-93.
14. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol. 150:1993;110-114.
15. Rosen M.A., Goldstone L., Lapin S., et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol. 148:1992;331-337.
16. Bigg S.W., Kavoussi L.R., Catalona W.S. Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol. 144:1990;1420-1424.
17. Trapasso J.G., deKernion J.B., Smith R.B., et al. The incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol. 152:1994;1821-1825.
18. Lange PH, Ercole CJ, and Vessella RL: Serum prostatic specific antigen in the management of patients after radical prostatectomy. J Urol 139(Pt 2): 607A, 1988.
19. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is PSA of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 149:1993;516-518.
20. Bazinet M., Zheng W., Begin L.R., et al. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 49:1997;721-725.
21. Gleave M.E., Sato N., Bowden M., et al. Neoadjuvant androgen ablation reduces local recurrence rates after tumour excision in the Shionogi tumour model. J Urol. 157:1997;1727-1730.
22. Sayer J., Ramirez E.I., von Eschenbach A.C. Retrospective review of prostate cancer patients with lymph node metastases. J Urol. 147:1992;52A.
23. Cheng C.W., Bergstralh E.J., Zincke H. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer. 71:1993;996-1004.
24. Tenniswood M. Apoptosis, tumour invasion and prostate cancer. Br J Urol. 79:1997;27-34.
25. Kupelian P., Katcher J., Levin H., et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 48:1996;249-253.
26. Dillioglugil O., Leiban B.D., Kattan M.W., et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 50:1997;93-99.
27. Catalona W.J., Ramos C.G., Carvalhal G.F. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin. 49:1999;282-296.
28. Meyer F., Moore L., Bairati I., et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol. 162:1999;2024-2028.
29. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostatic carcinoma a preliminary report . Urology. 45:1995;839-845.
30. Gleave M.E., Goldenberg S.L., Warner J. Randomized comparative study of 3 vs 8 months neoadjuvant hormone therapy prior to radical prostatectomy biochemical and pathological effects . J Urol. 161:1999;154-159.